CSF2 and psoriasis vulgaris: In our study, GM-CSF inhibition by MOR012507 significantly ameliorated the severity of skin inflammation in the IMQPD model, lending additional support for the exploration of GM-CSF inhibition in the treatment of human plaque psoriasis in clinical trials.